Position in SRRK
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$4,236,705
+$449,862 QoQ
Shares Held
77,031
0.0% QoQ
Ownership
0.063%
of shares outstanding
% of Portfolio
0.90%
of 13F equity value
Holder Rank
#99
of 304 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SRRK Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Aisling Capital Management LP holds $451,349,309 across 13 Biotechnology names. SRRK ranks #6 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
4,589,611 | $341,834,227 | |
| 2 | GLUE |
Monte Rosa Therapeutics, Inc.
|
1,555,664 | $37,647,068 | |
| 3 | SNDX |
Syndax Pharmaceuticals Inc
|
1,316,806 | $28,785,379 | |
| 4 | BCAX |
Bicara Therapeutics Inc.
|
568,919 | $16,891,205 | |
| 5 | BBOT |
BridgeBio Oncology Therapeutics, Inc.
|
1,018,018 | $7,757,297 | |
| 6 | SRRK |
Scholar Rock Holding Corp
This page
|
77,031 | $4,236,705 | |
| 7 | URGN |
UroGen Pharma Ltd.
|
108,000 | $3,974,400 | |
| 8 | BMEA |
Biomea Fusion, Inc.
|
2,048,757 | $3,011,672 |
All Filings in SRRK
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,236,705 | 77,031 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $3,786,843 | 77,031 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $3,393,215 | 77,031 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $2,868,634 | 77,031 | Shares | Sole | 2025-11-12 | |
| No filing history on record for this holder in this stock. | ||||||